Floatz logo

OTL-38

Lung Carcinoma

On Target Laboratories, LLCSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

67 Active assets in the Lung Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Carboplatin
SystImmune Inc.
Phase 3B
Nivolumab
M.D. Anderson Cancer Center
Phase 2B
Pembrolizumab
Essen Biotech
Phase 2B

View all 50 →

Same molecule, other indications

OTL-38 is also rated in:

ovarian cancerDormant
BB
Indicative ·
67 / 100
View asset →
childhood malignant neoplasmDormant
B
Indicative ·
60 / 100
View asset →
Childhood Malignant Thoracic NeoplasmDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →